Secondly, it also opens up the ability for our clinical development teams to more aggressively pursue additional development of Cinryze, whether it would be our subcutaneous administration program or other serious conditions of unmet need that could benefit from C1 inhibitor.I am very proud of the can do attitude of the joint ViroPharma/Sanquin team in achieving the PAS approval. And I am extremely thankful to the patients, physicians, HAEA and many others for their willingness to work with us and work through any challenges that confronted us. I would also like to note the efforts of the FDA’s CBER review team, who also worked together with us in a very professional manner.
ViroPharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.